Janssen Pharmaceutical Companies of Johnson & Johnson and Apple have today announced the launch of a new Heartline Study app designed to explore if the new app together with the heart health features on Apple Watch can help in reducing the risk of stroke with earlier detection of atrial fibrillation (AFib).
For those who aren’t familiar, AFib is a common form of irregular heart rhythm and is one of the leading causes of stroke in the U.S. The Heartline Study app is offering eligible U.S. adults 65 years and older the opportunity to join the clinical study by downloading and installing the app on their iPhones.
“Through this important collaboration with Apple, we are pioneering new models that we hope can break down some of the most common barriers to participation in clinical studies,” said Paul Burton, Vice President Janssen Scientific Affairs.
“Heartline is a study that has the potential to fundamentally change our understanding of how digital health tools, like the ECG app and irregular rhythm notification feature on Apple Watch, could lead to earlier detection of AFib, helping patients understand and directly engage in their heart health, prompting potentially life-saving conversations with their doctors, and improving health outcomes,” notes Dr. C. Michael Gibson*, Co-Chair of the Heartline Executive Committee and Professor of Medicine, Harvard Medical School and CEO, Baim Institute.
The app will enable participants to engage in the study remotely, right from their iPhone and in some cases an Apple Watch, rather than travel to a clinical trial site. To determine eligibility to participate and to download the app, visit Heartline.com.
